| Literature DB >> 35057541 |
Ricardo Usategui-Martín1,2, Daniel-Antonio De Luis-Román3,4,5, José María Fernández-Gómez6, Marta Ruiz-Mambrilla7, José-Luis Pérez-Castrillón4,5,8.
Abstract
The vitamin D receptor (VDR), a member of the nuclear receptor superfamily of transcriptional regulators, is crucial to calcitriol signalling. VDR is regulated by genetic and environmental factors and it is hypothesised that the response to vitamin D supplementation could be modulated by genetic variants in the VDR gene. The best studied polymorphisms in the VDR gene are Apal (rs7975232), BsmI (rs1544410), Taql (rs731236) and Fokl (rs10735810). We conducted a systematic review and meta-analysis to evaluate the response to vitamin D supplementation according to the BsmI, TaqI, ApaI and FokI polymorphisms. We included studies that analysed the relationship between the response to vitamin D supplementation and the genotypic distribution of these polymorphisms. We included eight studies that enrolled 1038 subjects. The results showed no significant association with the BsmI and ApaI polymorphisms (p = 0.081 and p = 0.63) and that the variant allele (Tt+tt) of the TaqI polymorphism and the FF genotype of the FokI variant were associated with a better response to vitamin D supplementation (p = 0.02 and p < 0.001). In conclusion, the TaqI and FokI polymorphisms could play a role in the modulation of the response to vitamin D supplementation, as they are associated with a better response to supplementation.Entities:
Keywords: FokI; TaqI; VDR; polymorphisms; vitamin D; vitamin D receptor; vitamin D supplementation
Mesh:
Substances:
Year: 2022 PMID: 35057541 PMCID: PMC8780067 DOI: 10.3390/nu14020360
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow chart of the studies selected for inclusion in the meta-analysis.
Characteristics of the studies included in the meta-analysis.
| Authors, Year | N | Age | Gender [n (%)] | Country | Vitamin D Dose | Follow-Up Time | |
|---|---|---|---|---|---|---|---|
| Women | Men | ||||||
| Graafmans et al., 1997 | 81 | 78 (5) | 81 (100%) | 0 (0%) | Netherlands | 400 IU/24 h | 12 months |
| Arabi et al., 2009 | 167 | 10 to 17 | 167 (100%) | 0 (0%) | Lebanon | 1100 IU/24 h | 12 months |
| Neyestani et al., 2013 | 140 | 29 to 67 | - | - | Iran | 1000 IU/24 h | 3 months |
| Sanwalka et al., 2015 | 102 | 11.2 (0.5) | 102 (100%) | 0 (0%) | India | 333 IU/24 h | 12 months |
| Al-Daghri et al., 2017 | 199 | >18 | 114 (57.2%) | 90 (42.8%) | Saudi Arabia | 2000 IU/24 h | 12 months |
| Mohseni et al., 2018 | 26 | 47.7 (8.0) | 26 (100%) | 0 (0%) | Iran | 7000 IU/24 h | 2 months |
| Pérez-Alonso et al., 2019 | 142 | 55 (4) | 142 (100%) | 0 (0%) | Spain | 800 IU/24 h | 3 months |
| Kazemian et al., 2020 | 176 | 48.6 (8.7) | 176 (100%) | 0 (0%) | Iran | 4000 IU/24 h | 3 months |
SD: standard deviation, IU: international units.
Baseline and post-supplementation vitamin D levels according to the BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene.
| Authors, Year | Vitamin D Levels BEFORE Supplementation, ng/mL [Mean (SD)] | Vitamin D Levels AFTER Supplementation, ng/mL [Mean (SD)] | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rs1544410 (BsmI) | rs731236 (TaqI) | rs7975232 (ApaI) | rs10735810 (FokI) | rs1544410 (BsmI) | rs731236 (TaqI) | rs7975232 (ApaI) | rs10735810 (FokI) | |||||||||
| BB | Bd+dd | TT | Tt+tt | AA | Aa+aa | FF | Ff+ff | BB | Bd+dd | TT | Tt+tt | AA | Aa+aa | FF | Ff+ff | |
| Graafmans et al., 1997 | 26 (7.5) | 29.2 (8.5) | - | - | - | - | - | - | 30.1 (10.1) | 25.75 (14.8) | - | - | - | - | - | - |
| Arabi et al., 2009 | 14.3 (9.4) | 14.25 (7.9) | 14.0 (8.5) | 13.9 (7.7) | - | - | - | - | 27.64 (14.5) | 26.11 (12.3) | 23.39 (15.6) | 29.64 (15.5) | - | - | - | - |
| Neyestani et al., 2013 | - | - | - | - | - | - | 38.1 (21.5) | 37.9 (16.7) | - | - | - | - | - | - | 73.6 (25) | 65 (24.3) |
| Sanwalka et al., 2015 | - | - | - | - | - | - | 27.77 (3.1) | 22.8 (2.04) | - | - | - | - | - | - | 61.72 (6.2) | 47.02 (8.9) |
| Al-Daghri et al., 2017 | 31.1 (14) | 34 (11.1) | 31.9 (12.7) | 33.8 (11.6) | 35.1 (9.5) | 33.3 (12.4) | 33 (12.4) | 34.8 (11.1) | 50.1 (14.7) | 55.6 (17.3) | 51.2 (13.6) | 55.4 (17.8) | 56.2 (13.3) | 54 (18.2) | 57.4 (17.3) | 47.9 (13.8) |
| Mohseni et al., 2018 | 9.0 (1.4) | 12.75 (1.4) | 16.5 (4.6) | 12.2 (1.5) | 13.6 (1.3) | 13.6 (2.7) | 13.0 (1.0) | 11.2 (1.4) | 11.0 (1.4) | 16.7 (4.3) | 11.5 (1.2) | 14.6 (1.5) | 14.8 (3.2) | 14.6 (3.1) | 28.0 (12) | 15.3 (3.1) |
| Pérez-Alonso et al., 2019 | 21 (10) | 24.5 (9) | 25 (9) | 23 (9.5) | 23 (10) | 24 (9) | - | - | 28 (9) | 30.5 (10) | 31 (8) | 30 (9) | 29 (9.5) | 31.1 (9.5) | - | - |
| Kazemian et al., 2020 | 30.2 (11.4) | 41.7 (16.9) | 31.8 (10.4) | 37.4 (11.3) | 40.9 (14.2) | 31.35 (11.4) | 34.4 (12.4) | 30.8 (9.4) | 99.3 (34) | 131.2 (29) | 105.3 (31.5) | 118.9 (29.4) | 111 (21.4) | 98.3 (23) | 114.9 (34) | 107.8 (23) |
SD: standard deviation.
Figure 2Meta-analysis of the association between gene variants in the vitamin D receptor (VDR) gene and the response to vitamin D supplementation. (A) Association between the BsmI polymorphism and the response to vitamin D supplementation. Test for overall effect: Z = 0.24 (p = 0.81). Test for heterogeneity: χ2 = 6.31 (p < 0.001), I2 = 9.4%. (B) Association between the TaqI polymorphism and the response to vitamin D supplementation. Test for overall effect: Z = 2.30 (p = 0.02). Test for heterogeneity: χ2 = 19.47 (p < 0.001), I2 = 10%. (C) Association between the ApaI polymorphism and the response to vitamin D supplementation. Test for overall effect: Z = 0.48 (p = 0.63). Test for heterogeneity: χ2 = 1.24 (p = 0.004), I2 = 7.7%. (D) Association between the FokI polymorphism and the response to vitamin D supplementation. Test for overall effect: Z = 9.39 (p < 0.001). Test for heterogeneity: χ2 = 2.47 (p = 0.04), I2 = 5.9%.